Association between serum fibroblast growth factor 21 and mortality among patients with coronary artery disease

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 12, 2016, Pages 4886-4894

  Li, Qing ^a,d   Zhang, Yuan ^b   Ding, Ding ^a   Yang, Yunou ^a   Chen, Qian ^a,c   Su, Dongfang ^a   Chen, Xuechen ^a   Yang, Wenqi ^a   Qiu, Jian ^b   Ling, Wenhua ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

^c PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^d GUILIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; FIBROBLAST GROWTH FACTOR 21; LIPID; FIBROBLAST GROWTH FACTOR;

ADULT; AGE; ARTICLE; BODY MASS; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FEMALE; FIBROBLAST GROWTH FACTOR 21 BLOOD LEVEL; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RISK ASSESSMENT; WAIST CIRCUMFERENCE; AGED; BLOOD; CARDIOVASCULAR DISEASES; CHINA; MIDDLE AGED; MORTALITY; RISK; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CHINA; CORONARY ARTERY DISEASE; FEMALE; FIBROBLAST GROWTH FACTORS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RISK;

EID: 85003758672     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2016-2308     Document Type: Article

References (49)

1. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: Part I: General considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104(22):2746-2753
2. World Health Organization. China: WHO Statistical Profile. Geneva, Switzerland: WHO Press; 2015
3. Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet. 20(11)04;20:563-569
4. Inagaki T, Dutchak P, Zhao G, et al. Endocrine regulation of the fasting response by PPAR-mediated induction of fibroblast growth factor 21. Cell Metab. 2007;5(6):415-425
5. Beenken A, Mohammadi M. The FGF family: Biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009;8(3):235-253
6. Woo YC, Xu A, Wang Y, Lam KS. Fibroblast growth factor 21 as an emerging metabolic regulator: Clinical perspectives. Clin Endocrinol (Oxf). 2013;78:489-496
7. Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115(6):1627-1635
8. Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta. 2000;1492(1):203-206
9. Dutchak PA, Katafuchi T, Bookout AL, et al. Fibroblast growth factor-21 regulates PPAR- activity and the antidiabetic actions of thiazolidinediones. Cell. 2012;148(3):556-567
10. Moyers JS, Shiyanova TL, Mehrbod F, et al. Molecular determinants of FGF-21 activity-synergy and cross-talk with PPAR- signaling. J Cell Physiol. 2007;210(1):1-6
11. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPAR-and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007;5(6):426-437
12. Kharitonenkov A, Wroblewski VJ, Koester A, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology. 2007;148(2):774-781
13. Coskun T, Bina HA, Schneider MA, et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology. 2008;149(12):6018-6027
14. Badman MK, Koester A, Flier JS, Kharitonenkov A, Maratos-Flier E. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology. 2009;150(11):4931-4940
15. Planavila A, Redondo-Angulo I, Ribas F, et al. Fibroblast growth factor 21 protects the heart from oxidative stress. Cardiovasc Res. 2015;106(1):19-31
16. Shen Y, Ma X, Zhou J, et al. Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovasc Diabetol. 2013;12:124
17. An SY, Lee MS, Yi SA, et al. Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques. Diabetes Res Clin Pract. 2012;96(2):196-203
18. Chow WS, Xu A, Woo YC, et al. Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2013;33(10):2454-2459
19. Lin Z, Wu Z, Yin X, et al. Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS One. 2010;5(12):e15534
20. Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: Executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina). Circulation. 199(21)9;99: 2829-2848
21. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-STsegment elevation myocardial infarction: Executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). Circulation. 2000;102(10):1193-1209
22. Li X, Zhang Y, Wang M, et al. The prevalence and awareness of cardiometabolic risk factors in Southern Chinese population with coronary artery disease. ScientificWorldJournal. 2013;2013:416192
23. Ding D, Qiu J, Li X, et al. Hyperglycemia and mortality among patients with coronary artery disease. Diabetes Care. 2014;37(2): 546-554
24. Moons KG, Donders RA, Stijnen T, Harrell FE Jr. Using the outcome for imputation of missing predictor values was preferred. J Clin Epidemiol. 2006;59(10):1092-1101
25. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735-2752
26. Semba RD, Crasto C, Strait J, Sun K, Schaumberg DA, Ferrucci L. Elevated serum fibroblast growth factor 21 is associated with hypertension in community-dwelling adults. J Hum Hypertens. 2013; 27(6):397-399
27. Bobbert T, Schwarz F, Fischer-Rosinsky A, et al. Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes in Caucasians. Diabetes Care. 2013;36(1):145-149
28. Chen C, Cheung BM, Tso AW, et al. High plasma level of fibroblast growth factor 21 is an independent predictor of type 2 diabetes: A 5.4-year population-based prospective study in Chinese subjects. Diabetes Care. 2011;34(9):2113-2115
29. Li H, Dong K, Fang Q, et al. High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: A 3-year prospective study in China. J Hepatol. 2013;58(3): 557-563
30. Zhang X, Yeung DC, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes. 2008;57(5):1246-1253
31. Li H, Bao Y, Xu A, et al. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and -glutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab. 2009;94(6):2151-2156
32. Lenart-Lipiska M, Matyjaszek-Matuszek B, Gernand W, Nowakowski A, Solski J. Serum fibroblast growth factor 21 is predictive of combined cardiovascular morbidity and mortality in patients with type 2 diabetes at a relatively short-term follow-up. Diabetes Res Clin Pract. 2013;101(2):194-200
33. Hotta Y, Nakamura H, Konishi M, et al. Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology. 2009; 150(10):4625-4633
34. Luo Y, McKeehan WL. Stressed liver and muscle call on adipocytes with FGF21. Front Endocrinol (Lausanne). 2013;4:194
35. Lee P, Linderman JD, Smith S, et al. Irisin and FGF21 are cold induced endocrine activators of brown fat function in humans. Cell Metab. 2014;19(2):302-309
36. Itoh N. FGF21 as a hepatokine, adipokine, and myokine in metabolism and diseases. Front Endocrinol (Lausanne). 2014;5:107
37. Wu X, Qi YF, Chang JR, et al. Possible role of fibroblast growth factor 21 on atherosclerosis via amelioration of endoplasmic reticulum stress-mediated apoptosis in apoE(-/-) mice. Heart Vessels. 2015;30(5):657-668
38. Lin Z, Pan X, Wu F, et al. Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory elementbinding protein-2 and induction of adiponectin in mice. Circulation. 2015;131(21):1861-1871
39. Xu J, Lloyd DJ, Hale C, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes. 2009;58(1):250-259
40. Zhang X, Hu Y, Zeng H, et al. Serum fibroblast growth factor 21 levels is associated with lower extremity atherosclerotic disease in Chinese female diabetic patients. Cardiovasc Diabetol. 2015;14:32
41. Lin Y, Xiao YC, Zhu H, et al. Serum fibroblast growth factor 21 levels are correlated with the severity of diabetic retinopathy. J Diabetes Res. 2014;2014:929756
42. Yilmaz Y, Eren F, Yonal O, et al. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest. 2010;40(10):887-892
43. Xiao F, Lin M, Huang P, et al. Elevated serum fibroblast growth factor 21 levels in patients with hyperthyroidism. J Clin Endocrinol Metab. 2015;100(10):3800-3805
44. Angelin B, Larsson TE, Rudling M. Circulating fibroblast growth factors as metabolic regulators- A critical appraisal. Cell Metab. 2012;16(6):693-705
45. Fisher FM, Chui PC, Antonellis PJ, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes. 2010;59(11): 2781-2789
46. Mraz M, Bartlova M, Lacinova Z, et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf). 2009;71:369-375
47. Lee Y, Lim S, Hong ES, et al. Serum FGF21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status. Clin Endocrinol (Oxf). 2014;80:57-64
48. Zhang Y, Lei T, Huang JF, et al. The link between fibroblast growth factor 21 and sterol regulatory element binding protein 1c during lipogenesis in hepatocytes. Mol Cell Endocrinol. 2011;342(1-2): 41-76
49. Jin QR, Bando Y, Miyawaki K, et al. Correlation of fibroblast growth factor 21 serum levels with metabolic parameters in Japanese subjects. J Med Invest. 2014;61(1-2):28-34.